Research To Practice | Oncology Videos

By Dr Neil Love

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigato... more

4.6

116116 ratings

FAQs about Research To Practice | Oncology Videos:

How many episodes does Research To Practice | Oncology Videos have?

The podcast currently has 3,073 episodes available.

Best of Research To Practice | Oncology Videos

The most played episodes among Podcast App listeners.

Number 1: Metastatic Triple-Negative Breast Cancer — Patterns of Care
Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics: Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00) First-Line Therapy (PD-L1 Negative) (6:53) First-Line Therapy (PD-L1 Positive) (23:40) Second-Line Therapy (Sequencing) (34:08) Adverse Events with TROP2-Targeting ADCs (43:43) CME information and select publications
August 28, 20261h 3min
Number 2: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Hope S Rugo, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 2: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Hope S Rugo, MD CME information and select publications
August 23, 202645min
Number 3: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Virginia Kaklamani, MD, DSc
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 1: Identification of Appropriate Candidates with HR-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway; Role in the Up-Front Setting — Virginia Kaklamani, MD, DSc CME information and select publications
August 23, 202615min
Number 4: AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29) CME information and select publications
August 22, 202619min
Number 5: Metastatic Bladder Cancer — Rapid Case Review Issue 6
Featuring perspectives from Prof Yohann Loriot, including the following topics: Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00) Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00) Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40) CME information and select publications
August 18, 202626min